Information Provided By: 
Fly News Breaks for November 18, 2019
TNDM
Nov 18, 2019 | 05:35 EDT
Piper Jaffray analyst Matt O'Brien took over coverage of Tandem Diabetes and reiterates an Overweight rating on the shares with an unchanged price target of $70. The analyst says that wlthough there was a pause to the "positive drumbeat" for the company during Q3 as a result of deferred pump purchases as patients and clinicians waited for Control-IQ, he still expects "significant revenue" growth from Tandem going forward.
News For TNDM From the Last 2 Days
TNDM
Apr 25, 2024 | 06:13 EDT
TNDM
Apr 25, 2024 | 06:02 EDT
Leerink upgraded Tandem Diabetes to Outperform from Market Perform with a $45 price target.
